Smith M F
Laryngoscope. 1985 Oct;95(10):1202-3. doi: 10.1288/00005537-198510000-00010.
5-Fluorouracil was introduced in the early 1960s as a topical chemotherapeutic agent and has become increasingly accepted because of its efficacy, economy, and relative absence of side effects in treating many pre-cancerous conditions, certain benign and malignant tumors, and dermatoses. This paper addresses the use of topical 5-fluorouracil in the management of cholesteatoma and unwanted mucus-secreting cells. A retrospective study has suggested a very impressive efficacy of topical 5-fluorouracil in the management of cholesteatoma and, to a lesser degree, control of hyper-mucus-secreting cells at locations in the middle ear and mastoid. The use of topical 5-fluorouracil in the management of hyperkeratosis, cholesteatoma in the middle ear and mastoid, and in the external canal has been almost 100% effective with very few side effects. In the management of hyper-mucous-secreting cells, 5-fluorouracil has a success rate of approximately 50%.
5-氟尿嘧啶于20世纪60年代初作为一种局部化疗药物被引入，由于其在治疗许多癌前病变、某些良性和恶性肿瘤以及皮肤病方面的有效性、经济性和相对较少的副作用，已越来越被人们所接受。本文探讨局部应用5-氟尿嘧啶治疗胆脂瘤和多余黏液分泌细胞的情况。一项回顾性研究表明，局部应用5-氟尿嘧啶治疗胆脂瘤效果显著，在一定程度上还能控制中耳和乳突部位的高黏液分泌细胞。局部应用5-氟尿嘧啶治疗角化过度、中耳和乳突胆脂瘤以及外耳道疾病，几乎100%有效，且副作用极少。在治疗高黏液分泌细胞方面，5-氟尿嘧啶的成功率约为50%。
